Loading...
In the randomized, placebo-controlled Lipid Study of ACCORD (Action to Control Cardiovascular Risk in Diabetes), researchers found a lack of efficacy for what was then a blockbuster drug — fenofibrate — in patients with diabetes who were taking statins. Now, investigators have reported outcomes of the study participants 5 years after the study ended.
Findings from this passive follow-up study largely confirmed the original results. With a mean of 9.7 years of follow-up data, there was still no evidence of efficacy (although only 4% continued on fenofibrate after the study's end). In fact, the results appeared the same at the end of ACCORD and at this follow-up. There remained a concerning and highly significant association of fenofibrate wit…